Which lasts longer — and why the question needs a qualifier

The short answer: ChondroFiller lasts substantially longer. Clinical outcome data indicate that 70–85% of patients sustain meaningful symptom relief for three to five years from a single treatment course, whereas hyaluronic acid typically provides benefit for six to twelve months before a repeat injection cycle becomes necessary.

But the comparison needs a qualifier — one that changes the clinical picture considerably. ChondroFiller is indicated specifically for localised, deep cartilage defects (Grade III or IV), where the goal is to provide an acellular scaffold that recruits the patient's own progenitor cells to promote endogenous repair at the defect site. Hyaluronic acid, by contrast, is designed for mild-to-moderate osteoarthritis across a broader joint surface, where restoring the lubricating properties of synovial fluid is the realistic and appropriate aim.

A patient with diffuse osteoarthritis would not be a candidate for ChondroFiller regardless of its longer durability profile. The question 'which lasts longer?' therefore only becomes clinically useful once the underlying diagnosis — focal structural lesion versus widespread degenerative change — has been established. The sections that follow explain how each treatment works and why that distinction shapes everything about the decision.

How ChondroFiller works as an injectable scaffold

Once injected under ultrasound guidance into the cartilage defect, ChondroFiller's collagen matrix gels within approximately three to five minutes — forming a dimensionally stable hydrogel that fills the lesion without requiring fibrin glue, biopsy, or any surgical procedure. The entire treatment is completed in a single outpatient appointment.

The gel's role is both structural and biological. As an acellular scaffold of murine-derived type I collagen, it provides a three-dimensional matrix that signals to the body's own progenitor cells — drawing them into the defect from surrounding synovium and subchondral bone through a process called acellular matrix-induced chondrogenesis. No cells are introduced from outside; the scaffold supports the body's own repair processes by creating the physical and chemical environment for cell migration and, over time, potential differentiation into cartilage-like tissue.

The most direct published evidence for this cell-recruitment mechanism comes from a 2025 ex vivo study that recorded a 2.4-fold increase in DNA content within the scaffold by day 14 post-application — early-stage laboratory data, but the clearest direct confirmation to date that host cells actively migrate into the matrix rather than the scaffold sitting passively at the defect site.

The collagen matrix itself resorbs progressively over one to two years as this repair process unfolds. Optimal tissue maturation is typically observed at 12 to 24 months post-treatment, which is why short-term follow-up alone understates the full benefit of the approach.

What hyaluronic acid injections actually do

Hyaluronic acid (HA) is an endogenous component of both synovial fluid and cartilage matrix, and in a healthy joint it gives synovial fluid its characteristic viscous, shock-absorbing quality. In osteoarthritis, HA concentration and molecular weight both decline, reducing the fluid's ability to lubricate articular surfaces. Injected viscosupplementation aims to restore that lubricating environment — improving the sliding ability of damaged cartilage surfaces and dampening mechanical irritation within the joint.

Most protocols require a course of one to five weekly injections, varying by product formulation, and the cycle is typically repeated as benefit diminishes over the following six to twelve months. This places HA firmly in the category of ongoing symptom management rather than a single-course intervention.

The evidence base is substantial: Cochrane and PRISMA-compliant systematic reviews consistently confirm short-term symptomatic benefit for mild-to-moderate knee osteoarthritis — reduced pain, improved function, tolerable safety profile. Cartilage regeneration is neither a claimed nor a demonstrated outcome of viscosupplementation. Guideline opinion, however, is divided: OARSI offers conditional support, while AAOS and ACR have taken a more sceptical position, reflecting disagreements over effect size and clinical relevance across the wider trial literature.

One area of active research involves HA-binding peptide–polymer composites, which have shown the potential to increase HA residence time at the cartilage surface beyond that of standard formulations. These remain investigational, and their clinical benefit over conventional HA products has not yet been established in large trials.

Duration evidence: what the data actually show

Those longevity figures carry important caveats. The 70–85% of patients sustaining meaningful symptom relief over three to five years, and the roughly 30-point IKDC improvement above baseline recorded across multiple cohorts, both derive from observational data and the manufacturer's Version 09 Clinical Evaluation Report published in April 2025 — not from a large, independent, double-blind randomised controlled trial comparing ChondroFiller directly against HA. Around 80% of treated patients in available series rated their results as good or very good and said they would choose the treatment again. These are clinically meaningful numbers, but the absence of a head-to-head RCT means no direct superiority claim can be made on current evidence; what the data establish is that the mechanism and durability profile differ substantially between the two interventions.

HA's trajectory is both better-powered at the trial level and shorter in its effect window: Cochrane and PRISMA-compliant systematic reviews confirm short-term symptomatic benefit for mild-to-moderate OA, but that benefit typically requires re-treatment within six to twelve months, making repeat injection cycles the expected maintenance pattern rather than the exception.

The maintenance picture for ChondroFiller is structured differently. Under a lifetime joint-preservation programme, a two-yearly top-up injection — combined with annual peptide therapy and MRI monitoring — is the recommended approach to sustain the repair environment and delay progression. This is a planned, infrequent intervention at a defined clinical juncture, not the rolling repeat cycle that HA entails.

For wider perspective on the injection landscape: corticosteroids, the most commonly used comparator, typically provide relief lasting weeks to a few months, and frequent repeat use carries its own risks. nSTRIDE, an autologous protein solution that acts on inflammatory mediators rather than the structural defect, is sometimes cited as the only single-injection therapy with benefit potentially extending to three years in its own indication — a useful durability reference point, though it operates through a different mechanism and suits a different patient group. Neither comparator belongs in the same regenerative scaffold category as ChondroFiller.

The right treatment depends on the type of cartilage problem

Establishing which pathway applies begins with imaging. An MRI that characterises defect depth, size, and cartilage grade does work that patient history and X-ray alone cannot: it distinguishes a focal, full-thickness lesion from the broader, diffuse thinning of osteoarthritis. Where a Grade III or IV focal defect is confirmed — discrete, contained, without generalised joint degeneration — the structural repair argument for a collagen scaffold becomes relevant. Where the picture shows diffuse cartilage loss across the joint surface, symptom management remains the appropriate goal, and HA viscosupplementation sits squarely within that aim.

The nuance that sometimes complicates this is that the two presentations can coexist: a patient may have a focal defect within a joint that also carries mild background OA. In such cases, clinical assessment needs to determine whether the focal lesion is the primary driver of symptoms — and whether the surrounding tissue and patient profile support endogenous repair — before a scaffold pathway is considered appropriate.

For patients in the UK, ChondroFiller carries CE marking as a Class III medical device, which covers both EU and current UK clinical use. Its regulatory status in the United States is unconfirmed, making it less accessible to patients seeking treatment outside the EU and UK. That geographic note is worth raising at consultation if travel or international care is a factor.

Getting the right assessment in London

Duration, in the end, is the wrong first question. The more useful starting point is whether the cartilage problem is structural or symptomatic — focal and deep, or diffuse and degenerative — because that determines which pathway belongs on the table at all. A patient with a contained Grade III lesion and a patient with generalised joint thinning are not weighing the same options, even if both are asking how long an injection lasts.

That distinction emerges from imaging, not from symptom history alone. An MRI that characterises defect grade, depth, and extent gives a clinician something to act on; without it, the duration comparison remains theoretical. For patients in London seeking that assessment, the London Cartilage Clinic on Harley Street — where Professor Paul Y. F. Lee leads cartilage evaluation — offers MRI review and clinical appraisal to map exactly that picture. The injectable ChondroFiller pathway there is an ultrasound-guided outpatient procedure, requiring no surgical admission.

Patients wishing to explore a cartilage assessment can book via londoncartilage.com.